Impact of replacement therapy for subclinical hypothyroidism on cardiovascular risk markers in patients with type 2 diabetes mellitus


Cite item

Full Text

Abstract

Aim. To study the time course changes in the parameters of endothelial dysfunction in patients with type 2 diabetes mellitus (DM) and subclinical hypothyroidism (SH) in the natural course of SH and during replacement therapy. Subjects and methods. All the examined patients were divided into 2 groups: 1) 67 patients received replacement therapy with euthyrox in a dose of 25 to 100 µg/day; 2) 60 patients were followed up. Results. At the moment of study inclusion, there was a close direct correlation between the levels of cholesterol and the aggregate intima-media thickness (IMT) (r=0.7) and between IMT and the levels of sICAM-1 (r=0.71) and sVCAM-1 (r=0.8). In the dynamics of the disease (following a year), the above correlations became weaker due to the performed treatment. A weak positive correlation was found between the aggregate IMT and the levels of sICAM-1 (r=0.2) and sVCAM-1 (r=0.3). Conclusion. In patients with type 2 DM, the presence of SH serves as an additional risk factor for endothelial dysfunction. Replacement therapy will be able to considerably retard the progression of the disease and to reduce the incidence of vascular events.

About the authors

S G Kasatkina

ГОУ ВПО "Астраханская государственная медицинская академия" Минздравсоцразвития России

Email: Svetlanaagma@yandex.ru

T N Panova

ГОУ ВПО "Астраханская государственная медицинская академия" Минздравсоцразвития России

References

  1. Helfand M. Screening for subclinical thyroid dysfunction in non-pregnant adults: a summary of the evidence for the US Preventive Services Task Force Ann Intern Med 2004; 140: 128-141.
  2. McDermott M.T., Ridgway E.C. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001; 86: 4585-4590.
  3. Дедов И.И., Шестакова М.В. Сахарный диабет. М: Универсум Паблишинг 2003; 455.
  4. Балахонова Т.В. Ультразвуковое исследование артерий у пациентов с сердечно-сосудистыми заболеваниями: Автореф. дис. ... д-ра мед. наук. М 2002.
  5. Libby P., Ridker P., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1147.
  6. Huo Y., Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 2001; 173 (1): 35-43.
  7. Malik I., Danesh J., Whincup P. et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 971-975.
  8. Patti G., Chello M., Pasceri V. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 17: 48 (8): 1560-1566.
  9. Tomiyasu H., Ishikawa K., Yamamoto M. Effect of anticholesterol therapy on soluble 1CAM-1 in chronic stroke patients with hyperlipidemia. Tokai J Exp Clin Med 2005; 30 (1): 63-69.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies